Third Quarter 2026
Filed Nov 4, 2026Ocugen reported third-quarter 2026 results, advanced three Phase 3 modifier gene therapy programs, and said cash, cash equivalents, restricted cash, and short-term investments of $84.6 million are expected to extend runway into 2028.
The company reported lower quarterly net loss per common share and higher collaborative arrangement revenue, while operating expenses increased and the business remains dependent on clinical, regulatory, and partnership milestones for its late-stage pipeline.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaborative arrangement revenue, three months ended September 30, 2026GAAP | $1.95M | – | – |
| Total revenue, three months ended September 30, 2026GAAP | 1.95M | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | 12.5M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | 7.20M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $19.70M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −17.75M | – | – |
| Interest income, three months ended September 30, 2026GAAP | 649K | – | – |
| Interest expense, three months ended September 30, 2026GAAP | −3.09M | – | – |
| Change in fair value of derivative liability, three months ended September 30, 2026GAAP | 16.56M | – | – |
| Other (expense) income, net, three months ended September 30, 2026GAAP | 34K | – | – |
| Total other (expense) income, three months ended September 30, 2026GAAP | $14.15M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$3.60M | – | – |
| Foreign currency translation adjustment, three months ended September 30, 2026GAAP | 26K | – | – |
| Unrealized loss on short-term investments, three months ended September 30, 2026GAAP | −93K | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$3.67M | – | – |
| Net loss attributable to common shareholders, basic and diluted, three months ended September 30, 2026GAAP | −3.60M | – | – |
| Weighted shares used in calculating net loss per common share, basic and diluted, three months ended September 30, 2026GAAP | 339,214,302 | – | – |
| Net loss per share attributable to common shareholders, basic and diluted, three months ended September 30, 2026GAAP | $ (0.01) | – | – |
| Collaborative arrangement revenue, nine months ended September 30, 2026GAAP | $4.97M | – | – |
| Total revenue, nine months ended September 30, 2026GAAP | 4.97M | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | 34.45M | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | 22.56M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $57.01M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −52.03M | – | – |
| Interest income, nine months ended September 30, 2026GAAP | 1.17M | – | – |
| Interest expense, nine months ended September 30, 2026GAAP | −8.89M | – | – |
| Loss on extinguishment of debt, nine months ended September 30, 2026GAAP | −2.38M | – | – |
| Change in fair value of derivative liability, nine months ended September 30, 2026GAAP | 14.67M | – | – |
| Other (expense) income, net, nine months ended September 30, 2026GAAP | −194K | – | – |
| Total other (expense) income, nine months ended September 30, 2026GAAP | $4.38M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$47.65M | – | – |
| Foreign currency translation adjustment, nine months ended September 30, 2026GAAP | 179K | – | – |
| Unrealized loss on short-term investments, nine months ended September 30, 2026GAAP | −93K | – | – |
| Comprehensive loss, nine months ended September 30, 2026GAAP | −$47.57M | – | – |
| Net loss attributable to common shareholders, basic and diluted, nine months ended September 30, 2026GAAP | −47.65M | – | – |
| Weighted shares used in calculating net loss per common share, basic and diluted, nine months ended September 30, 2026GAAP | 335,188,753 | – | – |
| Net loss per share attributable to common shareholders, basic and diluted, nine months ended September 30, 2026GAAP | $ (0.14) | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Future milestones and cash runway outlook
- NoteCash, cash equivalents, restricted cash, and short-term investments of $84.6 million as of September 30, 2026, is expected to extend the runway into 2028
- NoteTop-line data from the 140-patient Phase 3 liMeliGhT trial are expected in the first quarter of 2027
- NotePotential patient enrollment as early as year-end for OCU400 in The Bahamas
- NoteTopline data from the Phase 2/3 pivotal confirmatory trial (N=63 subjects) are anticipated in the second quarter of 2027
- NoteA planned Biologics License Application submission is expected to follow OCU400 top-line data
- NoteA planned Biologics License Application submission is expected to follow OCU410ST topline data
What drove it
- Received Provisional Approval and Priority Designation for OCU400 from the Longevity and Regenerative Therapies Board of The Bahamas.
- Executed an agreement with Global Alliance for Regenerative Medicine to coordinate and manage patient care for OCU400 in The Bahamas.
- Executed an exclusive OCU400 license agreement for the Middle East and North Africa with Roots Pharmaceutical.
- Ocugen is eligible under the Roots Pharmaceutical agreement for up to $4 million in combined upfront license fee and potential initial development milestone payments, up to $255 million of potential sales milestones, and a 22% royalty on net sales.
- Initiated dosing in the 240-subject global Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy.
- Completed Process Performance Qualification batches to support the OCU400 Biologics License Application and commercial launch supply.
- Named Jolanda Crombach General Manager of its newly established European affiliate in Amsterdam.
Concerns
- Loss from operations was (17,753) (in thousands) for the three months ended September 30, 2026.
- Interest expense was (3,090) (in thousands) for the three months ended September 30, 2026.
- The company reported a derivative liability of 17,146 (in thousands) and convertible notes of 83,117 (in thousands) as of September 30, 2026.
- The company stated that provisional LARTA approval and priority designation may not lead to faster regulatory review and full approval.
- The company stated that preliminary, interim, and top-line clinical trial results may not be indicative of, and may differ from, final clinical data.
What to watch
- Final LARTA approval and potential OCU400 patient enrollment in The Bahamas as early as year-end.
- Top-line data from the 140-patient Phase 3 liMeliGhT trial in the first quarter of 2027.
- Topline data from the OCU410ST Phase 2/3 pivotal confirmatory trial, with N=63 subjects, in the second quarter of 2027.
- Enrollment and 12-month geographic atrophy lesion-growth endpoint execution in the 240-subject OCU410 ArMaDa3 Phase 3 trial.
- Progress toward planned Biologics License Application submissions following OCU400 and OCU410ST data readouts.
- Cash runway expectation into 2028.
Balance sheet and cash flow
- Cash and cash equivalents as of September 30, 2026: $ 24,632 (in thousands); December 31, 2025: $ 18,571 (in thousands)
- Short-term investments as of September 30, 2026: 59,625 (in thousands); December 31, 2025: - (in thousands)
- Restricted cash as of September 30, 2026: 321 (in thousands); December 31, 2025: 316 (in thousands)
- Cash, cash equivalents, restricted cash, and short-term investments totaled $84.6 million as of September 30, 2026
- Total current assets as of September 30, 2026: 91,427 (in thousands); December 31, 2025: 24,340 (in thousands)
- Total assets as of September 30, 2026: $ 108,061 (in thousands); December 31, 2025: $ 43,516 (in thousands)
- Convertible notes as of September 30, 2026: 83,117 (in thousands); December 31, 2025: - (in thousands)
- Current portion of long-term debt as of September 30, 2026: 35 (in thousands); December 31, 2025: 1,250 (in thousands)
- Long term debt, net as of September 30, 2026: 1,743 (in thousands); December 31, 2025: 27,542 (in thousands)
- Derivative liability as of September 30, 2026: 17,146 (in thousands); December 31, 2025: - (in thousands)
- Total current liabilities as of September 30, 2026: 118,901 (in thousands); December 31, 2025: 23,043 (in thousands)
- Total non-current liabilities as of September 30, 2026: 6,841 (in thousands); December 31, 2025: 32,639 (in thousands)
- Total liabilities as of September 30, 2026: $ 125,742 (in thousands); December 31, 2025: $ 55,682 (in thousands)
- Total stockholders' equity (deficit) as of September 30, 2026: (17,681) (in thousands); December 31, 2025: (12,166) (in thousands)
- Common stock outstanding as of September 30, 2026: 339.3 million shares
Analysis
Ocugen's third-quarter results reflect a development-stage company with limited collaborative arrangement revenue and a pipeline centered on late-stage gene therapy programs. Total revenue for the three months ended September 30, 2026 was 1,951 (in thousands), compared with 1,752 (in thousands) in the prior-year quarter. The company reported a net loss of $ (3,598) (in thousands), compared with $ (20,051) (in thousands), and net loss per share of $ (0.01), compared with $ (0.07).
Operating spending was broadly stable at a total level but shifted toward research and development. Total operating expenses were $ 19,704 (in thousands), compared with $ 19,377 (in thousands). Research and development expenses were 12,500 (in thousands), compared with 11,149 (in thousands), while general and administrative expenses were 7,204 (in thousands), compared with 8,228 (in thousands). Loss from operations was (17,753) (in thousands), compared with (17,625) (in thousands).
The quarterly net loss benefited from a 16,562 (in thousands) change in fair value of derivative liability, which contributed to total other income of $ 14,155 (in thousands). Interest expense was (3,090) (in thousands), compared with (1,314) (in thousands). For the nine months ended September 30, 2026, total operating expenses were $ 57,008 (in thousands), loss from operations was (52,035) (in thousands), and net loss was $ (47,653) (in thousands).
Liquidity was reported as $84.6 million of cash, cash equivalents, restricted cash, and short-term investments as of September 30, 2026, with expected runway into 2028. The balance sheet also reported 83,117 (in thousands) of convertible notes, 17,146 (in thousands) of derivative liability, total liabilities of $ 125,742 (in thousands), and total stockholders' equity (deficit) of (17,681) (in thousands). No operating cash flow, free cash flow, share repurchases, or dividends were reported in the release.
The principal operating catalysts are clinical and regulatory. Ocugen received provisional approval and priority designation for OCU400 in The Bahamas, signed a MENA license with Roots Pharmaceutical, and initiated dosing in the 240-subject Phase 3 ArMaDa3 trial of OCU410. Management expects OCU400 Phase 3 liMeliGhT top-line data in the first quarter of 2027 and OCU410ST Phase 2/3 pivotal confirmatory-trial topline data in the second quarter of 2027. Execution against these readouts, progress toward regulatory submissions, and realization of the Roots agreement's potential payments and royalty economics are the key reported items to monitor.
Management, verbatim
With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide.
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder
As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder
Not in the filing
stated, not guessed- Gross profit and gross margin were not reported.
- Non-GAAP financial measures were not reported.
- Prior-quarter financial comparisons were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Capital expenditures were not reported.
- Share repurchases and dividends were not reported.
- Segment revenue and segment profitability were not reported.
- Revenue, gross margin, operating expense, and tax-rate financial guidance were not reported.
- No previous outlook section was provided, so comparison with prior guidance is unavailable.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.